Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +207.5% | +40.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +207.5% over three years. Forward estimates point to Revenue at +40.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc. TSX:EPRX.TO | $783.37M | $11.65 | Not rated | -8.6 | +0.80% |
Profound Medical Corp. TSX:PRN.TO | $388.24M | $10.60 | Not rated | -6.3 | +16.06% |
Canopy Growth Corporation TSX:WEED.TO | $364.19M | $0.81 | Not rated | -1.8 | -51.35% |
Medical Facilities Corporation TSX:DR.TO | $274.81M | $16.95 | Undervalued | 8.7 | +22.92% |
TerrAscend Corp. TSX:TSND.TO | $201.10M | $0.54 | Not rated | -2.5 | -1.89% |
OrganiGram Holdings Inc. TSX:OGI.TO | $166.39M | $1.18 | Not rated | -7.2 | -54.72% |
Helix BioPharma Corp. TSX:HBP.TO | $64.92M | $0.85 | Not rated | -32.6 | -64.90% |
Continue the stock analysis
Jump to another research area for this company.